Analysis of intravitreal bevacizumab treatment for macular oedema due to retinal vein occlusion
| Autor: | Szabolcs Balla, Eszter Zöld, Attila Vajas, Balazs Lukucz, Bernadett Ujhelyi, Valeria Nagy, László Potor |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Retinal Vein genetic structures Angiogenesis Inhibitors Macular oedema 030204 cardiovascular system & hematology Macular Edema 03 medical and health sciences 0302 clinical medicine Ophthalmology Retinal Vein Occlusion Occlusion medicine Humans Intravitreal bevacizumab Retina business.industry General Medicine medicine.disease eye diseases Bevacizumab Treatment Outcome medicine.anatomical_structure Intravitreal Injections 030221 ophthalmology & optometry Branch retinal vein occlusion business Tomography Optical Coherence |
| Zdroj: | European Journal of Ophthalmology. 31:2528-2534 |
| ISSN: | 1724-6016 1120-6721 |
| DOI: | 10.1177/1120672120962051 |
| Popis: | Purpose: Our aim was to analyse the clinical effect of intravitreal bevacizumab treatment for macular oedema due to central/branch retinal vein occlusion (CRVO/BRVO). The end points were final best-corrected visual acuity (BCVA), BCVA improvement, final central 1-mm macular subfield thickness (CST) and change in CST. Methods: Our study included 34 CRVO and 25 BRVO patients. Patients received intravitreal bevacizumab (IVB) treatment at our department. Our control group consisted of 50 CRVO and 30 BRVO patients, who had not received this treatment because their disease developed before the anti-VEGF treatment became available. For statistical analysis, two-sample t-test, Pearson’s correlation, and ANOVA were used. The level of significance was defined at p Results: With the two-sample t-test we found significant improvement of BCVA in the IVB-treated group (CRVO: 0.171 ± 0.270, p1 = 3.25×10-4; BRVO: 0.215 ± 0.282, p2 = 5.52×10-4). The difference in BCVA improvement was also significant compared to the control group (CRVO: p1 = 3.46×10-4; BRVO: p2 = 0.003). Significant decrease was observed in the CST in the treated group (CRVO: -345.114 ± 280.577, p1 = 6.94×10-9; BRVO: –151.875 ± 174.341, p2 = 1.67×10-4). In case of BRVO patients the final BCVA was significantly better in the treated group (0.617 ± 0.334) compared to the control group (0.406 ± 0.357), p = 0.016. Conclusion: IVB treatment results in significantly better final visual acuity and leads to significantly increased BCVA improvement compared to patients with RVO-induced macular oedema receiving no treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|